Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of…
Height Gain is Maintained in 2nd Year of Treatment
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University…
-
Noosa News22 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General20 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Noosa News23 hours agoAustralian NFL player Laki Tasi comes home to convince kids to switch codes
-
Business22 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000